4 › 4.1 › 4.1.4
4.1.4 Specific populations at risk
Pages 20–21 · open in PDF
Recommendations in this section
- Class ILevel AStrict blood pressure control (systolic blood pressure target <130 mmHg) is recommended in patients with hypertension or stage B HF to reduce the risk of HF.
- Class ILevel AAn SGLT2-I is recommended in patients with T2DM at risk of HF (multiple ASCVD risk factors or established ASCVD) to reduce the risk of HF and CV death.
- Class ILevel AAn SGLT2-I is recommended in patients with T2DM and CKD to reduce the risk of HF or CV death.
- Class ILevel AFinerenone is recommended in patients with T2DM and CKD to reduce the risk of HF.
- Class ILevel CCounselling on healthy lifestyle choices including maintaining a healthy weight, consuming a well-balanced diet, avoiding sedentary behaviour, abstaining from smoking and heavy alcohol consumption as well as counselling against the use of drugs such as cocaine, amphetamines, and anabolic steroids is recommended for all patients with stage A or B HF to reduce the risk of HF progression.
- Class IIaLevel ATreatment with a statin should be considered in people at high risk of, or with established ASCVD, to reduce the risk of HF.
- Class IIaLevel AA GLP-1 RA should be considered in patients with T2DM and at least one other additional CV risk factor to reduce the risk of HF or CV death.
Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.
Page 20 · PDF
including maintaining a healthy weight,
A meta-analysis of BETAMI–DANBLOCK and the REBOOT-CNIC trials showed no difference in major CV outcomes.121
consuming a well-balanced diet, avoiding sedentary behaviour, abstaining from smoking
4.1.4.3. Chronic kidney disease
Counselling on healthy lifestyle choices
and heavy alcohol consumption as well as counselling against the use of drugs such as cocaine, amphetamines, and anabolic steroids is
Chronic kidney disease is a strong risk marker for future HF risk, and efforts should be undertaken to optimize the control of concomitant risk factors (diabetes, hypertension, ASCVD) to prevent or delay HF onset.76 There is strong evidence that both SGLT2-Is and finerenone lower HF risk in patients with type 2 diabetes mellitus (T2DM) and CKD.104–108 Recommendations on specific preventive treatments for patients with CKD and CVD are outlined in the 2026 ESC Guidelines on cardiovascular disease and chronic kidney disease.122
recommended for all patients with stage A or B HF to reduce the risk of HF progression.74,84,85,87,91,95–100,109–112 Treatment with a statin should be considered in people at high risk of, or with established A GLP-1 RA should be considered in patients with T2DM and at least one other additional CV risk factor to reduce the risk of HF or CV death.71,113,114
ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; CV, cardiovascular; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HF, heart failure; SGLT2-I, sodium– glucose co-transporter 2 inhibitor; T2DM, type 2 diabetes mellitus. a Class of recommendation. b Level of evidence. c CKD was defined as follows: an eGFR 25–75 mL/min/1.73 m2 and a urinary albuminto-creatinine ratio ≥200–5000 mg/g in DAPA-CKD; an eGFR 20–45 mL/min/1.73 m2 or an eGFR 45–90 mL/min/1.73 m2 with a urinary albumin-to-creatinine ratio ≥200 mg/g in EMPA-KIDNEY; and eGFR 30–<90 mL/min/1.73 m2 with a urinary albumin-to-creatinine ratio >300 to ≤5000 mg/g in CREDENCE.115–117 d CKD was defined as follows: an eGFR 25–60 mL/min/1.73 m2, a urinary albumin-tocreatinine ratio 30–300 mg/g, and diabetic retinopathy, or an eGFR 25–75 mL/min/ 1.73 m2 and a urinary albumin-to-creatinine ratio 300–5000 mg/g, in FIDELIODKD106; and an eGFR 25–90 mL/min/1.73 m2 and a urinary albumin-to-creatinine ratio 30 to <300 mg/g, or an eGFR >60 mL/min/1.73 m2 and a urinary albumin-tocreatinine ratio 300–5000 mg/g, in FIGARO-DKD107.
4.1.4. Specific populations at risk 4.1.4.1. Arrhythmias Atrial fibrillation (AF) and other supraventricular tachyarrhythmias, as well as frequent ventricular ectopy and conduction disease, can all lead to HF. Prevention of HF in these conditions mainly relates to treatment of the underlying condition, which is covered in the 2024 ESC Guidelines for the management of atrial fibrillation118 and the 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.119 Investigation of LV systolic dysfunction and for underlying causes driving the arrhythmia should be considered based on clinical presentation (e.g. genetic, infiltrative, or inflammatory cardiomyopathy). In some patients, AF may be a marker of especially subclinical HFpEF, and evaluation and treatment of common cardiometabolic and lifestyle-related risk factors is warranted in such patients.
4.1.4.2. Myocardial infarction Patients with MI are at high risk of HF even in absence of wall motion abnormalities or structural dysfunction. Treatment of cardiometabolic risk factors should be optimized. In post-MI patients with preserved LVEF (>50%), no difference in the risk of HF was shown for beta-blocker therapy vs placebo in the REDUCE-AMI trial, arguing against routine use of beta-blockers in this setting.120
ASCVD, to reduce the risk of HF.75
4.1.4.4. Cancer survivors Cancer survivors, especially those with prior radiation or exposure to cardiotoxic agents (anthracycline, cyclophosphamide, immune checkpoint inhibitors, trastuzumab) are at higher risk of asymptomatic LV systolic dysfunction and HF. The prevention of HF in these patients, as well as surveillance and risk modification strategies among those undergoing active cancer treatment, are outlined in the 2022 ESC Guidelines on cardio-oncology.6
4.1.4.5. Familial and genetic predisposition but no overt clinical disease Because modifiable risk factors are likely to be significant contributors to disease onset in many genetically predisposed individuals, optimal risk-factor control is recommended in individuals with familial or genetic predisposition to HF, but without clinical disease.123 In carriers of dilated cardiomyopathy (DCM), nondilated LV cardiomyopathy, or ARVC-related variants, regular follow-up and cardiac screening is suggested, according to the specific recommendations provided in the 2023 ESC Guidelines for the management of cardiomyopathies.124
4.1.4.6. Pulmonary disorders and sleep-disordered breathing Poor sleep quality, sleep-disordered breathing (SDB), sleep apnoea, and chronic obstructive pulmonary disease (COPD) are all associated with a higher incidence of HF.125–127 Recommendations for screening and treatment of these conditions are outlined in the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.61
4.1.4.7. Endocrine disorders Thyroid disorders, acromegaly, and pheochromocytoma are all associated with increased risk of HF.61,128 Prevention of HF is primarily related to correction of the underlying hormonal dysfunction and should otherwise follow the general principles outlined in this section.
4.1.4.8. Congenital heart disease Advances in surgical repair and life expectancy for patients with congenital heart disease have led to an increasing burden of HF in this population.129,130 Patients with congenital heart disease have an eight-fold overall increased relative risk of developing HF and are on average 20–25 years younger at the time of HF onset, compared with age- and sex-matched controls.131 The risk is greatest in complex lesions such as conotruncal defects
Page 21 · PDF
4.2.1. Asymptomatic left ventricular dysfunction Based on normal reference values of LVEF in adult populationbased samples, LV systolic dysfunction should be considered present if patients are asymptomatic and have an LVEF <50% in the absence of alternative explanations (e.g. athlete’s heart) for both men and women and regardless of age. Treatment with an ACE-I (or ARB if intolerant) if LVEF ≤40% and a beta-blocker if LVEF <50% are recommended to reduce the risk of HF and mortality. The evidence behind these recommendations are derived from the SOLVD-Prevention trial,135,136 which randomized patients with asymptomatic LV systolic dysfunction (LVEF ≤35%) to enalapril or placebo, and the TRACE137 and SAVE138 trials, which randomized patients post-MI with LVEF ≤35%–40% to trandolapril or placebo (TRACE) and captopril vs placebo (SAVE). These studies were conducted in the 1990s and contemporary management of multiple comorbidities (MI, diabetes, CKD) has since changed. One RCT, CAPRICORN, published in 2001, investigated beta-blockers post-MI in patients with LV systolic dysfunction, where patients were randomized to carvedilol or placebo.139 It should be noted that this trial allowed patients to receive intravenous (i.v.) diuretics for acute HF, but excluded those with continuous need for i.v. diuretics, meaning not all had truly asymptomatic LV systolic dysfunction. The hazard ratio (HR) for all-cause mortality was 0.77 [95% confidence interval (CI) 0.60–0.98] in the group receiving carvedilol vs placebo. Additional observational data from SOLVD and SAVE suggested similar improved outcomes with a beta-blocker.140–142 Further, the REVERT trial, which randomized asymptomatic patients with LVEF <40% to metoprolol extended release or placebo, showed that metoprolol reversed LV remodelling.142 The role of these drugs for asymptomatic individuals with mildly reduced LVEF (41%–49%) is not well studied, but their use is reasonable also in this range of LVEF given the shared pathophysiology with more depressed LV systolic function. A meta-analysis of BETAMI–DANBLOCK and REBOOT-CNIC showed a significant reduction in the combined endpoint of mortality, MI and HF with beta-blockers vs placebo in post-MI patients with stage B HF and mildly reduced LVEF.121 Careful follow-up to assess for progressive decline in LVEF is otherwise warranted for patients without treatment. Based on the results of the EPHESUS trial, eplerenone is recommended in patients after MI with LVEF ≤40% and diabetes to reduce the risk of HFH or death.143
4.2.2. Valvular heart disease Prevention of HF in patients with valvular disease should follow the recommendations outlined in the 2025 ESC/EACTS Guidelines for the management of valvular heart disease.9
Recommendations An ACE-I or ARB (if intolerant to ACE-I) is recommended in patients with stage B HF and LVEF ≤40% to reduce the risk of HFH and
death.135–138,144 A beta-blocker is recommended in patients with stage B HF and LVEF <50% to reduce the risk of HFH or death.35,139,140 Eplerenone is recommended in patients with LVEF ≤40% after myocardial infarction with signs of HF or diabetes to reduce the risk of HFH and death.143
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; HF, heart failure; HFH, heart failure hospitalization; LVEF, left ventricular ejection fraction. a Class of recommendation. b Level of evidence.
4.3. Risk prediction in patients with established heart failure Several risk scores have been developed to predict HFH and mortality among ambulatory patients with established HF, including e.g. the MAGGIC risk score,77 the Seattle Heart Failure Model,78 and the more recent ESC initiated LIFE-HF79 (HFrEF) and LIFE-Preserved (HFpEF).80 It should be noted that LIFE-HF included patients with LVEF ≤40% and LIFE-Preserved patients with LVEF ≥50%. The ESC scores therefore need to be validated for HFrEF patients in the upper range of LVEF (>40%–49%) and, ideally, in external samples across the entire LVEF spectrum before widespread implementation (see Supplementary data online, Section S1 and Figure S1). Although pharmacological treatments are indicated in patients with established HF regardless of estimated risks (as outlined in Section 6), these risk scores may be helpful in identifying high-risk patients that may benefit from closer follow-up and to facilitate discussions around patient goals of care.
5. Diagnosis of chronic heart failure 5.1. Key steps in the diagnosis of chronic heart failure The failing heart causes a clinical syndrome with a wide array of signs and symptoms, which vary in sensitivity and specificity (Table 7), and none of which are entirely characteristic. The severity of HF symptoms can be classified according to the New York Heart Association (NYHA) functional class (Table 8). Specialist assessment relies on clinical evaluation, the examination of individual risk factors, and previous medical history as well as 12-lead ECG and chest X-ray evaluation. Clinical suspicion should be followed by testing of natriuretic peptides and echocardiography (Figure 4). In the very elderly patients, suspicion should be raised even with an atypical presentation. A recent HFA consensus paper provides a diagnostic framework for general practice and non–cardiology-based physicians.145
4.2. Patients with stage B heart failure
Recommendation Table 2 — Recommendations for stage B heart failure and left ventricular dysfunction (see Evidence Table 16)
(e.g. tetralogy of Fallot, transposition of the great arteries, truncus arteriosus, double-outlet right or left ventricle, with up to 42-fold risk), and severe non-conotruncal defects (e.g. atrioventricular septal defects, single ventricle and hypoplastic left heart syndrome, with up to 21-fold increased risk).131 Conventional HF risk factors (e.g. CAD, hypertension, diabetes, and obesity) are common in patients with congenital heart disease and contribute significantly to HF risk.132–134 Careful attention to riskfactor modification is warranted as they are likely to contribute to the risk of developing HF.